Waiv
AI-powered precision diagnostics company for oncology, spun out of Owkin's diagnostics division (formerly Owkin Dx) in March 2026.
Press release · 12 Mar 2026
Paris, FranceProducts
Selected offerings — the AI products recorded here, not the vendor's full catalogue.
-
BRCAura RUO Data service
Research-use-only AI test assessing BRCA-related genomic risk signatures from pathology data, sold to research institutions rather than clinical end users.
-
Destra Platform
Workflow platform that orchestrates Waiv's diagnostic tests within a lab's existing pathology workflow, handling sample intake, result delivery and reporting.
-
MSIntuit Suite Data service
Suite of AI diagnostic tests covering colorectal, endometrial and gastric cancer screening from pathology slides, marketed as one branded product line on Waiv's own site.
-
RlapsRisk BC Data service
CE-IVDR-cleared AI diagnostic test that predicts breast-cancer recurrence risk from routine pathology data, spun out of Owkin's diagnostics division.
Similar products 22
No sourced competitor yet: no filing, vendor document or measured-market report read so far names a rival for this company, so none is asserted. The companies below are the closest by what their products do.
Tempus AIPublic · $12.4BOverlaps on data analysis; similar scale (public); ships agent platform and application rather than the same layer.1 of 2 capabilitiesDifferent layerCompareIT
Invisible TechnologiesPrivate · $144M raisedOverlaps on data analysis and workflow automation; similar scale (private).2 of 2 capabilitiesShared product typeCompareP
PresightPublic · $5.6BOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareVS
Verint SystemsAcquiredOverlaps on data analysis and workflow automation; Verint Systems is acquired, with no independent scale.2 of 2 capabilitiesShared product typeCompareA
AlphaSensePrivate · $7.5BOverlaps on data analysis; similar scale (private).1 of 2 capabilitiesShared product typeCompareS
SentinelOnePublic · $7.5BOverlaps on data analysis; similar scale (public).1 of 2 capabilitiesShared product typeCompareG
GenesysPrivateOverlaps on data analysis and workflow automation; Genesys's scale not recorded.2 of 2 capabilitiesShared product typeCompareS
SalesforcePublic · $196.1BOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareC
Copy.aiAcquired ($13.9M deal)Overlaps on data analysis and workflow automation; Copy.ai is acquired, with no independent scale.2 of 2 capabilitiesShared product typeCompareSE
Schneider ElectricPublic · $200.4BOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareU
UiPathPublic · $7.2BOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareN
NiCEPublic · $6.5BOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareW
WritesonicPrivateOverlaps on data analysis and workflow automation; Writesonic's scale not recorded; ships AI agent and application rather than the same layer.2 of 2 capabilitiesDifferent layerCompareI
IntuitPublic · $97.9BOverlaps on data analysis and workflow automation; similar scale (public); ships AI agent and application rather than the same layer.2 of 2 capabilitiesDifferent layerCompareI
IBMPublic · $216.6BOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareA
AmazonPublic · $2.8TOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareS
SuperhumanPrivateOverlaps on workflow automation; Superhuman's scale not recorded.1 of 2 capabilitiesShared product typeCompareD
DropboxPublic · $7.8BOverlaps on workflow automation; similar scale (public); ships application rather than the same layer.1 of 2 capabilitiesDifferent layerCompareK
KrispPrivateOverlaps on data analysis; Krisp's scale not recorded; ships application and developer tool rather than the same layer.1 of 2 capabilitiesDifferent layerCompareC
CrestaPrivate · $1.6BOverlaps on data analysis and workflow automation; similar scale (private); ships AI agent and application rather than the same layer.2 of 2 capabilitiesDifferent layerCompareP
PegasystemsPublic · $6.1BOverlaps on data analysis and workflow automation; similar scale (public).2 of 2 capabilitiesShared product typeCompareM
MoveworksAcquiredOverlaps on data analysis and workflow automation; Moveworks is acquired, with no independent scale; ships AI agent and application rather than the same layer.2 of 2 capabilitiesDifferent layerCompareClosest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.
Sources
- Total funding
-
Waiv's own release, 2026-04-24: "Waiv Closes $35 Million in Total Funding with New Investment from CRB Health Tech" -- a Series A extension (CRB Digital Health III) on top of the $33M co-led by OTB Ventures and Alpha Intelligence Capital announced 2026-03-12 alongside the spin-out itself. $35M is the most recent cumulative figure the company itself states.
- Founded
-
Dated from the spin-out announcement (2026-03-12), the same rule as any spin-out (see amp-frontier): the diagnostics work existed inside Owkin earlier, but the company is dated from its separation.
- Status
-
Official documentation · 13 Sep 2026
Fetched 2026-09-13: active newsroom through a 2026-05-06 Daiichi Sankyo collaboration announcement and a 2026-04-16 dual CE-IVDR marking for its breast and colorectal cancer tests. No wind-down or acquisition language.
- Description
-
Owkin's own newsfeed, 2026-03-12: "Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx." Corroborated by Waiv's own site (waiv.com, redirected from wearewaiv.com), which the diagnostics page links out to: "Waiv, a spin-out of Owkin, capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests." Two independent sources, both confirming a genuine spin-out rather than a rename or third-party divestment.
Something wrong here? Send a correction — quote this company id: waiv.